Long-chain fatty acid oxidation disorders
Ultragenyx Canada Inc
Call for patient/clinician input open:
Call for patient/clinician input closed:
Manufacturer Requested Reimbursement Criteria1:
Ultragenyx is requesting triheptanoin be reimbursed for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD)
Dojolvi (triheptanoin) is indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD).
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.